April 13, 2021
Kirill Dmitriev, CEO, RDIF - Alexei Druzhinin×
Russia and India will be the largest production hubs for Sputnik V, the Covid-19 vaccine developed by Russia’s Gamalaya Centre, said Kirill Dmitriev, Chief Executive Officer of the Russian Direct Investment Fund (RDIF). The Indian drug regulator gave its go-ahead to the vaccine on Tuesday.
Five production partnerships have already been tied up, and more would be announced in the next two weeks, said the chief of Russia’s sovereign wealth fund, and these could be with large pharmaceutical companies or partnerships to “fill finish” vaccines, he said.
While India would be the 60th country to approve Sputnik V, he did not clarify the number of doses that would be available for India. Production would commence shortly and touch 50 million doses a month by summer, he said, indicating that the roll-out could be by May. Other manufacturing hubs include Korea and China, he added.
China
India
Russia
Russian
Kirill-dmitriev
Russia-gamalaya-centre
Serum-institute
Russian-direct-investment-fund
Gamalaya-centre
Chief-executive-officer
Gland-pharma
Panacea-biotech